CHMP5 and COVID-19: Besides ARCT-154, at least four additional COVID-19 products based on saRNA are under scrutiny in clinical trials, including COVAC1 [5,6,7] and GEMCOVAC-OM [8], both expressing full-length, stabilized SARS-CoV-2 Spike, and VLPCOV-1 [9], along with its improved version, VLPCOV-2 [10], which express the Spike receptor-binding domain.